Androgen and androgen-metabolizing enzymes in metastasized lymph nodes of breast cancer.
暂无分享,去创建一个
Takashi Suzuki | H. Sasano | N. Ohuchi | K. McNamara | Yasuhiro Nakamura | K. Takagi | Y. Miki | Y. Shibahara | T. Ishida | K. Uchida | T. Yoda | S. Hata | Chikako Sakurada | Yasuhiro Nakamura
[1] Takashi Suzuki,et al. Androgen receptor in triple negative breast cancer , 2013, The Journal of Steroid Biochemistry and Molecular Biology.
[2] Takashi Suzuki,et al. Immunohistochemical analysis of aromatase in metastatic lymph nodes of breast cancer , 2013, Pathology international.
[3] P. Argani,et al. Androgen receptor expression is usually maintained in initial surgically resected breast cancer metastases but is often lost in end-stage metastases found at autopsy. , 2012, Human pathology.
[4] J. Carroll,et al. Minireview: The androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene? , 2012, Molecular endocrinology.
[5] S. Clark,et al. Androgen receptor expression predicts breast cancer survival: the role of genetic and epigenetic events , 2012, BMC Cancer.
[6] D Faratian,et al. Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] T. Traina,et al. Triple-Negative Breast Cancer: Role of the Androgen Receptor , 2010, Cancer journal.
[8] Li Jia,et al. Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. , 2009, Cancer research.
[9] M. Bani,et al. Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients. , 2009, Breast.
[10] A. León,et al. Androgens and androgen receptors in breast cancer , 2007, Journal of Steroid Biochemistry and Molecular Biology.
[11] Takashi Suzuki,et al. 5α‐Reductase type 1 and aromatase in breast carcinoma as regulators of in situ androgen production , 2007, International journal of cancer.
[12] Noriaki Ohuchi,et al. Sex steroid-producing enzymes in human breast cancer. , 2005, Endocrine-related cancer.
[13] L. Patrikainen,et al. Enzymes as modulators in malignant transformation , 2005, The Journal of Steroid Biochemistry and Molecular Biology.
[14] M. Bryś,et al. Androgen receptor status in female breast cancer: RT-PCR and Western blot studies , 2002, Journal of Cancer Research and Clinical Oncology.
[15] Takashi Suzuki,et al. 5alpha-reductases in human breast carcinoma: possible modulator of in situ androgenic actions. , 2001, The Journal of clinical endocrinology and metabolism.
[16] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[17] D. Allred,et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[18] S J Schnitt,et al. Interobserver Reproducibility in the Diagnosis of Ductal Proliferative Breast Lesions Using Standardized Criteria , 1992, The American journal of surgical pathology.
[19] J. Varhaug,et al. Androgen receptors in operable breast cancer: relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment. , 1992, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[20] B. Park,et al. Androgen receptor as a targeted therapy for breast cancer. , 2012, American journal of cancer research.
[21] I. Ellis,et al. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.
[22] L. Sobin,et al. TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.